March 2017

Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?

So far the discounts are meh. Physician and patient acceptance, not the usual bag of tricks, may determine market share and ultimate effect on prices.
Hundreds of products are at some stage of development, but only a handful may get on the market in the next few years.
When biologics go off-patent, copycat products could lower oncology expenditures by the millions, if not billions. But the discounts and future market share are far from certain.
Biosimilar companies want the six-month waiting period on sales to start as soon as they file their application, not when the FDA approves the product. The Supreme Court is hearing their case.
Why patient-friendly communication strategies are more important than ever.
Drugmakers and beneficiaries love coupons and patient-assistance programs, but they give PBMs and health plans a headache.


Legislation & Regulation
Diana Furchtgott-Roth, adviser to three Republican presidents, gives her take on the dismantling of the ACA and what may come after.
Health reimbursement arrangements are back and could mean health coverage for employees of small businesses. Skeptics believe few businesses will offer HRAs.
Payers and providers need to collaborate to manage costs. Encouraging use of generics and biosimilars is one way they can slow down the soaring drug spend.
That’s the danger when new medications are compared against placebo rather than against over-the-counter products with a history of effectiveness.